Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS). In addition to setmelanotide, it has two earlier-stage investigational MC4R agonists in clinical development, RM-718, designed for weekly administration, and bivamelagon, an oral small molecule.
종목 코드 RYTM
회사 이름Rhythm Pharmaceuticals Inc
상장일Oct 05, 2017
설립일2013
CEO- -
직원 수283
유형Ordinary Share
회계 연도 종료Oct 05
주소222 Berkeley Street
도시BOSTON
증권 거래소NASDAQ Global Market Consolidated
국가United States of America
우편 번호02116
전화18572644280
웹사이트https://rhythmtx.com/
종목 코드 RYTM
상장일Oct 05, 2017
설립일2013
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음